Treatment results of stage I and II oral tongue cancer with interstitial brachytherapy: Maximum tumor thickness is prognostic of nodal metastasis

Matsuura, K.; Hirokawa, Yutaka; Fujita, Minoru; Akagi, Yukio; Ito, Katsuhide

doi:10.1016/s0360-3016(97)00811-0

Cited by 52 publications

(24 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This signifies that brachytherapy alone is sufficient for T1 stage patients, and neck addressal is not required for these patients. The similar results have been described by various studies in literature too [1,3,4,6,10]. [23,24,25], by applying corrections for overall treatment time: T = 38 or 39 days = 28 days EBRT, 3 or 4 days brachytherapy boost (3 days when 18 Gy boost given in 3 days, and 4 days when 24 Gy boost given in 4 days), and 7 days gap prior to brachytherapy for mucosal reactions to heal), starting time of tumor repopulation (Tk = 21 days) and cell population doubling time during treatment done by EBRT and brachytherapy boost (Tp = 3 days):…”

Section: Discussionsupporting

confidence: 92%

“…But for early stage tongue cancers (stage I and II), interstitial brachytherapy is also considered an effective treatment modality as local control and survival results are equivalent to that of surgery [1,3]. Also, with brachytherapy, there is an added advantage of functional preservation of tongue.…”

Section: Discussionmentioning

confidence: 99%

“…Interstitial brachytherapy is one of the standard curative treatments used in early stage oral tongue cancer and is favored over surgery in view of better functional preservation [1]. With surgery, 5-year local control rates in early stage oral tongue cancer have been reported to approximately 75-90% [2].…”

Section: Purposementioning

confidence: 99%

“…With surgery, 5-year local control rates in early stage oral tongue cancer have been reported to approximately 75-90% [2]. Interstitial implants also provide local control rates equivalent to that of surgery [1,3]. However, most of the results in literature have been described with continuous low-dose-rate brachytherapy (LDR-BT) [4,5,6,7,8,9,10].…”

Section: Purposementioning

confidence: 99%

See 3 more Smart Citations

High-dose-rate interstitial brachytherapy in early stage oral tongue cancer – 15 year experience from a tertiary care institute

Bansal¹,

Ghoshal²,

Oinam³

et al. 2016

jcb

View full text Add to dashboard Cite

Purpose: To determine outcomes of interstitial high-dose-rate brachytherapy (HDR-BT) in patients with early stage oral tongue cancer.Material and methods: Ninety-two patients with stage I and II oral tongue cancer were treated with HDR-BT between 1999 and 2014: brachytherapy alone = 62 (67.4%), and combination of external beam radiotherapy (EBRT) and brachytherapy = 30 (32.6%). Median follow-up was 53.5 months. Patterns of failure, overall survival (OS), disease-free survival (DFS), local control rates (LCR), and nodal control rates (NCR) were determined.Results: 5-year OS, DFS, LCR, and NCR were 73.2%, 58.2%, 64.2%, and 83.8%, respectively. In total, 43 patients (46.7%) failed treatment: isolated local failures = 28 (30.4%), isolated nodal failures = 8 (8.7%), both local and regional failures = 7 (7.6%). While in T1 stage, 5 year LCR were significantly higher in brachytherapy alone group compared to combined EBRT and brachytherapy group (81.7% vs. 62.5%, p = 0.04), the isolated nodal failure rates were not significantly different among the two groups. For T2 stage, NCR were higher in combined EBRT and brachytherapy group compared to brachytherapy alone (92.9% vs. 74.3%). Acute mucositis (grade ≥ 2) was seen more in brachytherapy alone group compared to the combined modality group (87% vs. 66%), and this correlated significantly with the higher biological equivalent dose (BED) in the brachytherapy alone group.Conclusions: Our study recommends treating patients with brachytherapy alone in T1 stage, and demonstrates the need for addressing nodal region either by neck dissection or nodal irradiation in T2 stage patients. Also, the study highlights the need for dose escalation (from the doses used in the study) in both T1 and T2 stage tumors when using interstitial brachytherapy either as sole modality or as a boost.

show abstract

Section: Discussionsupporting

confidence: 92%

Section: Discussionmentioning

confidence: 99%

Section: Purposementioning

confidence: 99%

Section: Purposementioning

confidence: 99%

See 2 more Smart Citations

High-dose-rate interstitial brachytherapy in early stage oral tongue cancer – 15 year experience from a tertiary care institute

Bansal¹,

Ghoshal²,

Oinam³

et al. 2016

jcb

View full text Add to dashboard Cite

show abstract

“…T D and T T remain one dimensional measurements, and are subject criticisms similar to those aimed at surface diameter. In addition, several studies have concluded that T D and T T are of no value for predicting OM [14][15][16] or survival [16][17][18][19]. Further, the majority of studies have relied on the use of postoperative resected specimens.…”

Section: Discussionmentioning

confidence: 99%

Evaluating lingual carcinoma for surgical management: what does volumetric measurement with MRI offer?

Boland

Watt-Smith²,

Pataridis³

et al. 2010

BJR

View full text Add to dashboard Cite

ABSTRACT. MRI plays a crucial but under utilized role in the surgical management of lingual squamous cell carcinoma (SCC). Measurement of three-dimensional tumour volume (TV) has the potential to guide management of clinically negative cervical lymph nodes and address deficiencies in current TNM staging criteria. This work studied the value of MRI-measured TV as a predictor of 2 year disease-related survival (DRS) and disease-free survival (DFS), as well as occult cervical lymph node metastasis (OM) in lingual cancer. TV was determined by manually segmenting the tumour contour in each image slice and using the resulting pixel value to calculate the three-dimensional extent of disease. TV was also compared with the more established measure of tumour thickness (TT). Significant differences in DRS (x 2 (1) 5 7.7, Hazard ratio (HR) 5 7.3, p 5 0.005) and DFS (x 2 (1) 5 5.6, HR 5 4.3, p 5 0.02) at two years were found using a cut-off of 8 cm 3 . Similarly, a significant relationship between TV and occult cervical lymph node metastasis was discovered using a 3 cm 3 cut-off (OR 5 6.7, p 5 0.02, Fisher's Exact Test).

show abstract

Carcinoma of the Oral Cavity

Unger¹,

Ho²,

Melotek³

et al. 2017

Clinical Radiation Oncology

View full text Add to dashboard Cite

Treatment results of stage I and II oral tongue cancer with interstitial brachytherapy: Maximum tumor thickness is prognostic of nodal metastasis

Cited by 52 publications

References 26 publications

High-dose-rate interstitial brachytherapy in early stage oral tongue cancer – 15 year experience from a tertiary care institute

High-dose-rate interstitial brachytherapy in early stage oral tongue cancer – 15 year experience from a tertiary care institute

Evaluating lingual carcinoma for surgical management: what does volumetric measurement with MRI offer?

Carcinoma of the Oral Cavity

Contact Info

Product

Resources

About